Purpose The aim of our study was to evaluate the impact of CYP3A4, CYP3A5, and ABCB1
polymorphisms on donepezil disposition and clinical outcome. Methods Fifty-four Italian …

Objective The aims of this study were to evaluate the impact of the CYP2D6 polymorphism
on both the steady-state plasma concentrations (Cp) and the clinical outcome of donepezil …

Background: Donepezil is one of the most commonly prescribed drugs for the treatment of
Alzheimer disease. It is predominantly metabolized through CYP2D6 and to a lesser extent …

Objective Cytochrome P450 (CYP) 2D6 enzyme is the major responsible for the metabolism
of donepezil, an inhibitor of acetyl cholinesterase currently used for the symptomatic …

Aim: The impact of CYP2D6 and CYP3A4 polymorphism on the steady-state plasma
concentrations and therapeutic outcome of donepezil monotherapy and combination …

Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil
Efficacy in Alzheimer’s Disease Patients Page 1 Journal of Alzheimer’s Disease 30 (2012) …

Background Differential responses to donepezil treatment in patients with Alzheimer's
disease (AD) have been observed in clinical practice. It remains controversial whether, and …

Aims A large interindividual variability in plasma concentrations has been reported in
patients treated with donepezil, the most frequently prescribed antidementia drug. We aimed …

Background The aim of this study was to evaluate the effect of CYP2D6* 10 and APOE
polymorphisms on both steady-state plasma concentrations (Cp) and clinical response of …

Background Recent data indicate that the rs1080985 single nucleotide polymorphism of the
cytochrome P450 (CYP) 2D6 gene may affect the response to treatment with donepezil in …